Does every unilateral tinnitus need an MRI?

Not every case of unilateral tinnitus automatically requires MRI, but it is an indication that warrants clinical evaluation. An audiologist or ENT will assess the full picture: degree and pattern of any hearing loss, duration of symptoms, associated vertigo or imbalance, and ABR findings. MRI with gadolinium is ordered when the clinical picture raises suspicion for a retrocochlear lesion. The AAO-HNS guideline specifically recommends MRI evaluation for asymmetric SNHL.

Are vestibular schwannomas cancerous?

No. Vestibular schwannomas are benign tumors. They grow slowly and do not metastasize. The main concern is local mechanical compression: as the tumor grows, it can press on the eighth nerve (causing hearing loss and tinnitus), the seventh nerve (causing facial weakness), and in larger tumors, the brainstem. This is why monitoring and, when indicated, treatment are important even though the tumor itself is not malignant.

What are the treatment options for vestibular schwannoma?

The three main options are observation (active surveillance with serial MRI), stereotactic radiosurgery (Gamma Knife or CyberKnife), and microsurgical resection. The choice depends on tumor size, growth rate, patient age, existing hearing function, and patient preference. Many small, slow-growing tumors are managed with observation alone. A neurotologist or skull-base team discusses options based on individual findings.

Can a vestibular schwannoma cause tinnitus without hearing loss?

Yes. Tinnitus without measurable hearing loss is an uncommon but recognized presentation of vestibular schwannoma. It is one reason that unilateral tinnitus, even with normal audiometry, may warrant imaging in the right clinical context. An audiologist or ENT assesses this based on the overall clinical picture.

Vestibular schwannoma (acoustic neuroma): unilateral tinnitus red flag

Tinnitus in one ear, and only one ear, is a symptom worth taking seriously. Bilateral tinnitus is common and most often reflects noise exposure, age-related hearing change, or general auditory system changes that affect both sides. Tinnitus that is consistently and exclusively unilateral follows a shorter list of explanations, and vestibular schwannoma sits near the top of that list as the condition clinicians most want to rule out.

Vestibular schwannoma, also called acoustic neuroma (though neither nerve of origin nor tumor type makes “acoustic neuroma” strictly accurate), is a benign tumor arising from the Schwann cells that insulate the vestibular branch of the eighth cranial nerve. It grows slowly in the internal auditory canal and, as it enlarges, can compress the cochlear nerve, the facial nerve, and eventually the brainstem.

How common are vestibular schwannomas

The NIDCD estimates that about 3,000 to 4,000 vestibular schwannomas are newly diagnosed in the United States each year. The condition is not rare within the context of intracranial tumors, accounting for roughly 6 to 8 percent of all intracranial neoplasms by some estimates.

Most are sporadic, occurring in one ear without a genetic cause. Bilateral vestibular schwannomas are a hallmark of neurofibromatosis type 2 (NF2), a genetic condition caused by mutations in the NF2 tumor suppressor gene. Bilateral presentation should prompt evaluation for NF2.

The NIH StatPearls review notes that peak incidence is in the fifth and sixth decades of life, though tumors can develop at any adult age.

The symptom triad

The classic presentation of vestibular schwannoma involves three elements, though all three are not always present together.

Unilateral sensorineural hearing loss. This is the most common presenting symptom. The hearing loss is often gradual, which can make it easy to dismiss or attribute to other causes. A key audiometric feature is that word recognition scores are disproportionately worse than the degree of pure-tone loss would predict. This “rollover” pattern on speech audiometry reflects direct eighth nerve dysfunction rather than cochlear hair cell loss.

Unilateral tinnitus. Tinnitus is present in the majority of patients with vestibular schwannoma. It is typically high-pitched, constant, and confined to the affected ear. Mayo Clinic lists unilateral tinnitus as a key presenting symptom and one that should prompt evaluation.

Balance disturbance. Because the tumor arises from the vestibular nerve, vestibular dysfunction is expected. However, the slow growth of these tumors allows the central nervous system to compensate gradually, so many patients with vestibular schwannoma report only mild unsteadiness rather than acute vertigo. Acute vertigo attacks are less typical.

Facial numbness or weakness can occur with larger tumors that compress the seventh nerve, but these symptoms are uncommon at diagnosis because tumors are increasingly found when small.

Why prompt evaluation matters

The reason clinicians respond urgently to unilateral SNHL and tinnitus is not that vestibular schwannomas are immediately dangerous, most grow very slowly (often less than 1 to 2 mm per year) and some do not grow at all. The reason is that treatment options and outcomes are strongly influenced by tumor size at diagnosis.

A small intracanalicular tumor (confined to the internal auditory canal) can often be managed with surveillance or treated with radiosurgery with good hearing preservation rates. A tumor that has grown to 3 or 4 cm may be compressing the brainstem and carries surgical risks that include facial nerve injury and loss of any residual hearing.

The AAO-HNS clinical practice guideline specifically recommends obtaining MRI in patients with unexplained asymmetric SNHL. Auditory brainstem response (ABR) testing can suggest retrocochlear pathology and was historically used as a screening tool, but MRI with gadolinium contrast is the standard confirmatory study.

Imaging and diagnosis

MRI with gadolinium enhancement is the gold-standard imaging study. It can detect vestibular schwannomas as small as 1 to 2 mm. CT scanning without contrast is not adequate for reliably detecting small tumors.

High-resolution CT may be used in patients who cannot undergo MRI, for example due to certain implanted devices, but sensitivity is lower for small intracanalicular lesions.

The NIH StatPearls review notes that imaging is typically the investigation that confirms the diagnosis; tissue biopsy is rarely needed and not part of standard workup. The enhancement pattern on MRI is characteristic enough that diagnosis is made radiologically in most cases.

The surveillance versus treatment decision

A diagnosis of vestibular schwannoma does not automatically mean intervention. Many tumors, particularly small ones in older patients or those with limited functional hearing, are managed with active surveillance using serial MRI, often annually initially and then less frequently if growth is not observed.

When treatment is chosen, the two principal options are:

Stereotactic radiosurgery (Gamma Knife, CyberKnife, or proton beam) delivers focused radiation to the tumor in one to five sessions. It is not a traditional surgical procedure. The goal is tumor control rather than tumor removal. Radiosurgery has been shown to arrest growth in the large majority of treated tumors. Hearing preservation rates depend on pre-treatment hearing levels and tumor size.

Microsurgery is performed by a neurotologist and neurosurgeon together. The approach (translabyrinthine, retrosigmoid, or middle fossa) depends on tumor size and hearing levels. For tumors where hearing preservation surgery is not expected to maintain useful hearing, the translabyrinthine approach may be preferred for its access and lower rates of facial nerve injury in some series.

Tinnitus often persists after treatment regardless of approach. For patients in whom hearing is preserved, tinnitus may improve. For patients who lose hearing during surgery, tinnitus may persist or change character.

Living after diagnosis

A vestibular schwannoma diagnosis is anxiety-provoking, but the prognosis for life expectancy is excellent. The tumor is benign. The management challenge is preserving neurological function, particularly hearing and facial movement, while controlling tumor growth over decades of follow-up.

Many patients remain on long-term surveillance with no intervention and maintain useful hearing and quality of life for many years. Others require treatment at some point, either because of documented growth or because of patient preference to proceed.

If symptoms persist or change, see an audiologist or physician.